Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the al amyloidosis market grown over the years?

The market size for AL amyloidosis has experienced accelerated expansion recently. Projected growth from $3.11 billion in 2024 to $3.52 billion in 2025 is expected to take place at a compound annual growth rate (CAGR) of 13.2%. This substantial growth in the historical period can be credited to the increased awareness about AL amyloidosis amongst healthcare professionals, an upsurge in the AL amyloidosis cases, an increasing elderly populace, the broadening of diagnostic amenities, and enhancement in the field of cardiac imaging.

What Is the forecasted market size and growth rate for the al amyloidosis market?

In the upcoming years, the market size of AL amyloidosis is projected to expand swiftly, reaching a valuation of $5.74 billion by 2029 with a 13.0% CAGR. This expected growth during the forecast timeframe is due to an increase in blood cell DNA mutation instances, enhanced healthcare infrastructure, escalating occurrence of multiple myeloma, the onset of combination treatments, and heightened use of high-dosage chemotherapy. Key trends for this period comprise developments in diagnostic methods, progress in drug delivery technologies, innovations in blood testing, the rise of targeted therapies, and the implementation of AI in diagnosis.

Get your al amyloidosis market report here!

https://www.thebusinessresearchcompany.com/report/al-amyloidosis-global-market-report

What are the major factors driving growth in the al amyloidosis market?

The growth of the AL amyloidosis market is predicted to be accelerated by the increasing prevalence of plasma cell disorders. Abnormal plasma cells that produce either excessive or unusual antibodies characterize these disorders, potentially causing organ damage. Factors such as an aging demographic, improved life expectancy, and advancements in diagnostic technology are behind the rise in plasma cell disorders. AL amyloidosis develops from these disorders, particularly, the excessive production of abnormal light chain proteins. This can result in the accumulation of amyloid deposits in organs and tissues and intensifies the impacts of plasma cell dyscrasias. For instance, in August 2024, the American Cancer Society (ACS), a nonprofit organization based in the United States, published reports that anticipate around 35,780 new cases of multiple myeloma to be diagnosed (19,520 in men and 16,260 in women), with an expected 12,540 associated deaths (7,020 in men and 5,520 in women). Thus, the high incidence of plasma cell disorders is a significant driver of the AL amyloidosis market’s expansion.

What key areas define the segmentation of the global al amyloidosis Market?

The AL amyloidosis market covered in this report is segmented –

1) By Treatment: Chemotherapy, Supportive Care, Surgery, Stem Cell Transplant, Targeted Therapy

2) By Drugs: Transthyretin Transport Inhibitor, Immunomodulatory Drugs, Monoclonal Antibodies, Proteasome Inhibitors, Other Drugs

3) By Route Of Administration: Intravenous, Oral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Chemotherapy: Conventional Chemotherapy Agents, High-Dose Chemotherapy

2) By Supportive Care: Pain Management, Organ-specific Supportive Care (Cardiac, Renal)

3) By Surgery: Organ Transplantation, Debulking Surgery

4) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant

5) By Targeted Therapy: Monoclonal Antibodies, Proteasome Inhibitors, Kinase Inhibitors

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20710&type=smp

What are the top market players propelling the growth of the al amyloidosis industry?

Major companies operating in the AL amyloidosis market are Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Genmab A/S, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultromics Ltd, Neurimmune AG, Immix Biopharma Inc., Oncopeptides AB, Attralus Inc.

What key trends are currently impacting the al amyloidosis market’s development?

Leading businesses in the AL amyloidosis market are concentrating their efforts on the creation of novel therapies, specifically next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, in order to enhance treatment effectiveness and patient prognosis. This advanced immunotherapy technique involves modifying a patient’s T cells to identify and eliminate BCMA on cancer cells, particularly in multiple myeloma. For example, in September 2023, Immix Biopharma Inc., an American biopharmaceutical firm, was granted approval from the U.S. Food and Drug Administration (FDA) for the use of NXC-201 in the treatment of the life-threatening blood disorder, Amyloid Light Chain (AL) Amyloidosis. NXC-201, a next-generation CAR-T cell therapy, is currently under clinical trials for the treatment of amyloid light chain (AL) amyloidosis, and it has shown promising results with a 100% hematologic response rate and organ improvements in patients who were unresponsive to previous treatments.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20710

What regions are dominating the al amyloidosis market growth?

North America was the largest region in the AL amyloidosis market in 2024. The regions covered in the AL amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Convalescent Plasma Therapy Global Market Report 2025

https://thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report

Global Plasma Therapy Global Market Report 2025

https://thebusinessresearchcompany.com/report/plasmas-therapy-global-market-report

Mycoplasma Testing Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/mycoplasma-testing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: